Head-to-head Intra-individual Comparison of [ 68 Ga]-FAPI and [ 18 F]-FDG PET/CT in Patients with Bladder Cancer
E Novruzov, K Dendl, H Ndlovu, P L Choyke, M Dabir, M […]
Feasibility of [ 68 Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
Lena M Unterrainer, Simon Lindner, Lennert Eismann, Jozefina Casuscelli, Franz-Josef Gildehaus, Vinh […]
Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?
Chiara Da Pieve, Marta Costa Braga, David R Turton, Frank A Valla, […]
New Fully Automated Preparation of High Apparent Molar Activity 68 Ga-FAPI-46 on a Trasis AiO Platform
Chiara Da Pieve, Marta Costa Braga, David R Turton, Frank A Valla, […]
Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review
Liang Zhao, Jianhao Chen, Yizhen Pang, Kaili Fu, Qihang Shang, Hua Wu, […]
SOFIE gets greenlight from US FDA to proceed to Phase II Pancreatic Cancer Study
Dulles, VA – November 10, 2021 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?
Katharina Dendl 1,2 Stefan A. Koerber 3,4,5 Clemens Kratochwil 1 Jens […]
SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging
Dulles, VA – October 12, 2021 – SOFIE Biosciences (SOFIE), an established US manufacturer and […]
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress GalleryNew Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar-Oromieh, Frank Rösch, Axel […]
SOFIE promotes Scott Boller to Chief Financial Officer
SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, has promoted the company’s […]